AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23977977 — intervention group
Group type: COMPARATOR
Intervention: Framing therapeutic benefits as improvements in median survival
Number of subjects: 2040
Study 20951103 — intervention group
Group type: COMPARATOR
Intervention: Pro Children intervention
Number of subjects: 0
Study 20951103 — intervention group
Group type: COMPARATOR
Intervention: Schoolgruiten intervention
Number of subjects: 0
Study 20951103 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 0
Study 19248859 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 182
Study 19248859 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 182
Study 17365759 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted self-help condition (manual, targeted video, two support phone calls)
Number of subjects: 1069
Study 17365759 — intervention group
Group type: COMPARATOR
Intervention: Manual-only condition
Number of subjects: 1069
Study 15289213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil, 50 mg
Number of subjects: 14
Study 15289213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11450766 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 0
Study 9389781 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g (1 mg oestradiol) transdermal oestradiol gel continuously combined with 10 mg medroxyprogesterone acetate orally 12 days either monthly or every third month
Number of subjects: 48
Study 9389781 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study 7701266 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN + somatostatin
Number of subjects: 63
Study 7701266 — intervention group
Group type: COMPARATOR
Intervention: TPN alone
Number of subjects: 63
Study 2437753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium infusion (0.5 mg X kg‐1 bolus followed by 0.29‐0.44 mg X kg‐1 X h‐1 maintenance infusion)
Number of subjects: 0
Study 2437753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium infusion
Number of subjects: 0
Study 31246120 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (30% oxygen and 70% helium)
Number of subjects: 6
Study 31246120 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen (30% oxygen and 70% nitrogen)
Number of subjects: 6
Study 28893921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary potassium restriction with oral sodium polystyrene sulfonate if needed
Number of subjects: 47
Study 28893921 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice regarding general nutrition (Control)
Number of subjects: 47
Study 28893921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary potassium restriction
Number of subjects: 47
Study 25851691 — intervention group
Group type: COMPARATOR
Intervention: Selexipag alone
Number of subjects: 20
Study 25851691 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag with lopinavir/ritonavir (400/100 mg)
Number of subjects: 20
Study 25851691 — intervention group
Group type: COMPARATOR
Intervention: Selexipag alone or with lopinavir/ritonavir
Number of subjects: 20
Study 23504631 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine treatment group
Number of subjects: 50
Study 23504631 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 50
Study 21392640 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 499
Study 21392640 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel and placebo)
Number of subjects: 499
Study 19170145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (SHR‐5) pills
Number of subjects: 30
Study 19170145 — intervention group
Group type: COMPARATOR
Intervention: ADAPT‐232 supplements
Number of subjects: 30
Study 19170145 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 30
Study 16579328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse care coordination (NCC)
Number of subjects: 85
Study 16579328 — intervention group
Group type: COMPARATOR
Intervention: MCO services without nurse care coordination
Number of subjects: 85
Study 15288704 — intervention group
Group type: COMPARATOR
Intervention: Regular daily activities in control participants
Number of subjects: 100
Study 15288704 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activities in depressed participants
Number of subjects: 100
Study 11743593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times daily (n=20)
Number of subjects: 46
Study 11743593 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg twice daily (equivalent to 694 mg acyclovir twice daily) (n=18)
Number of subjects: 46
Study 11743593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=6)
Number of subjects: 46
Study 9437408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 150 micrograms/kg
Number of subjects: 8
Study 9437408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8297222 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (30mg twice daily, increased to 60mg three times a day)
Number of subjects: 31
Study 8297222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8297222 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 31
Study 3619586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen (1.5 mg/day)
Number of subjects: 40
Study 3619586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3619586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 40
Study 31315908 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg daily
Number of subjects: 66
Study 31315908 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg two times a day
Number of subjects: 66
Study 31315908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27159420 — intervention group
Group type: EXPERIMENTAL
Intervention: Step down dose of PPIs by half for 8 weeks
Number of subjects: 100
Study 27159420 — intervention group
Group type: COMPARATOR
Intervention: Continue with the same dose of PPIs for 8 weeks
Number of subjects: 100
Study 27159420 — intervention group
Group type: EXPERIMENTAL
Intervention: Step down dose of PPIs by half
Number of subjects: 100
Study 27159420 — intervention group
Group type: COMPARATOR
Intervention: Continue with the same dose of PPIs
Number of subjects: 100
Study 26026502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (6 g/day)
Number of subjects: 22
Study 26026502 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (6 g/day)
Number of subjects: 22
Study 24520987 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 28
Study 24520987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22674457 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1, 4, or 10 mg/kg plus standard therapy
Number of subjects: 364
Study 22674457 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg (after switching from placebo)
Number of subjects: 364
Study 22674457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 19752340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide, doxorubicin, and fluorouracil (CAF), with or without tamoxifen
Number of subjects: 1154
Study 19752340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide, doxorubicin, and fluorouracil (CAF), with tamoxifen
Number of subjects: 1154
Study 19752340 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1154
Study 17331828 — intervention group
Group type: EXPERIMENTAL
Intervention: True interval cancers
Number of subjects: 208
Study 17331828 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult interval cancers
Number of subjects: 208
Study 17331828 — intervention group
Group type: EXPERIMENTAL
Intervention: False-negative interval cancers
Number of subjects: 208
Study 17331828 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular microcalcification
Number of subjects: 208
Study 17331828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense background patterns
Number of subjects: 208
Study 15249757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-lysine
Number of subjects: 73
Study 15249757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 11199954 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus extract of ginkgo biloba (EGb)
Number of subjects: 82
Study 11199954 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus placebo
Number of subjects: 82
Study 10463317 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 8
Study 10463317 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg
Number of subjects: 8
Study 10463317 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg
Number of subjects: 8
Study 10463317 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 8
Study 10463317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7603608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline bicarbonate water (Donata)
Number of subjects: 10
Study 7603608 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 2665062 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (200 mg X 3)
Number of subjects: 38
Study 2665062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 226840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen
Number of subjects: 50
Study 226840 — intervention group
Group type: EXPERIMENTAL
Intervention: Other forms of exogenous estrogen
Number of subjects: 50
Study 226840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31975493 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied for 5 consecutive days over the right swallowing motor cortex
Number of subjects: 42
Study 31975493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (TBS) applied for 5 consecutive days over the right swallowing motor cortex
Number of subjects: 42
Study 31759295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PP group
Number of subjects: 660
Study 31759295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PPHP group
Number of subjects: 660
Study 31759295 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 660
Study 28715286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 126
Study 26214341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 13
Study 26214341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Core members of friendship groups
Number of subjects: 9500
Study 24389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolates
Number of subjects: 9500
Study 24389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaisons
Number of subjects: 9500
Study 22568247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Qubi Decoction (one bag/day for four weeks)
Number of subjects: 96
Study 22568247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Qubi Decoction
Number of subjects: 96
Study 22568247 — intervention group
Group type: COMPARATOR
Intervention: Diacerein (50 mg Bid, Po) and Celecoxib (0.2 Qd, Po) (control group)
Number of subjects: 96
Study 19195842 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg bid
Number of subjects: 59
Study 19195842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19195842 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 59
Study 17469006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine (5 mg as a slow bolus dose given intravenously, repeated every 20 minutes to a maximum of five doses)
Number of subjects: 82
Study 17469006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (20 mg in an intravenous bolus dose followed by 40 mg if not effective within 20 minutes, followed by 80 mg every 20 minutes to a maximum dose of 300 mg)
Number of subjects: 82
Study 14751924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-timing induction therapy
Number of subjects: 150
Study 14751924 — intervention group
Group type: COMPARATOR
Intervention: Standard-timing induction therapy
Number of subjects: 150
Study 14751924 — intervention group
Group type: EXPERIMENTAL
Intervention: No hepatomegaly at diagnosis
Number of subjects: 150
Study 14751924 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 3 and 4 acute GVHD
Number of subjects: 150
Study 14751924 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 1 or 2 GVHD
Number of subjects: 150
Study 14751924 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 10 years
Number of subjects: 150
Study 11226111 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional dextromethorphan (120 mg) IM 30 min before skin incision
Number of subjects: 60
Study 9763820 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoprophylactic lessons for childbirth
Number of subjects: 100
Study 9763820 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication during pregnancy
Number of subjects: 100
Study 9763820 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical assistance
Number of subjects: 100
Study 7529535 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF alone
Number of subjects: 19
Study 7529535 — intervention group
Group type: COMPARATOR
Intervention: CY + etoposide + G‐CSF
Number of subjects: 19
Study 7529535 — intervention group
Group type: COMPARATOR
Intervention: CY + GM‐CSF
Number of subjects: 19
Study 2913556 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein capsules
Number of subjects: 24
Study 2913556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (human albumin powder) capsules
Number of subjects: 24
Study 2913556 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-free diet (Nutramigen)
Number of subjects: 24
Study 2913556 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 24
Study 1164007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with valley levels over 2 mug/ml
Number of subjects: 86
Study 1164007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with peak levels over 10 mug/ml
Number of subjects: 86
Study 1164007 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin with peaks over 10 mug/ml
Number of subjects: 86
Study 1164007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin initial doses of 2.0, 1.5, and 1.3 or less mpk
Number of subjects: 86
Study 1164007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin loading dose of 2 mpk
Number of subjects: 86
Study 1164007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin at 4.5 mpk daily
Number of subjects: 86
Study 1164007 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin at 3.0 mpk daily
Number of subjects: 86
Study 31032356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB) via perineum with 0.25% ropivacaine plus 0.8% lidocaine (3-5ml)
Number of subjects: 104
Study 31032356 — intervention group
Group type: COMPARATOR
Intervention: Caudal Block (CB) with a dose of 0.5 ml/kg
Number of subjects: 104
Study 31032356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB)
Number of subjects: 104
Study 31032356 — intervention group
Group type: COMPARATOR
Intervention: Caudal Block (CB)
Number of subjects: 104
Study 29257010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (20 mg/kg before incision, 10 mg/kg at 3, 6, 12, and 24 hours) + Topical TXA (1 g) without tourniquet
Number of subjects: 150
Study 29257010 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet + Intravenous TXA + Topical TXA
Number of subjects: 150
Study 29257010 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet only
Number of subjects: 150
Study 26356105 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Group A)
Number of subjects: 59
Study 26356105 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 59
Study 23145894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P, n=58)
Number of subjects: 89
Study 23145894 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (Group NP, n=31)
Number of subjects: 89
Study 22379923 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg/day)
Number of subjects: 51
Study 22379923 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (80 mg/day)
Number of subjects: 51
Study 19938143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy
Number of subjects: 103
Study 19938143 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (tacrolimus, azathioprine, and steroids)
Number of subjects: 103
Study 17255126 — intervention group
Group type: COMPARATOR
Intervention: No exposure to RAS blockades
Number of subjects: 62
Study 17255126 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI alone
Number of subjects: 62
Study 17255126 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB alone
Number of subjects: 62
Study 17255126 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI+ARB combination
Number of subjects: 62
Study 15030341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied once daily
Number of subjects: 624
Study 15030341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied twice daily
Number of subjects: 624
Study 15030341 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate (HA) ointment applied twice daily
Number of subjects: 624
Study 15030341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment (both once and twice daily)
Number of subjects: 624
Study 11505807 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg daily for one month
Number of subjects: 40
Study 11505807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antihistamine)
Number of subjects: 40
Study 9755264 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine (acellular pertussis component DTP vaccine)
Number of subjects: 0
Study 9755264 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine (whole cell pertussis component DTP vaccine)
Number of subjects: 0
Study 9755264 — intervention group
Group type: COMPARATOR
Intervention: DT vaccine (diphtheria and tetanus toxoids vaccine)
Number of subjects: 0
Study 8113557 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic mapping approach
Number of subjects: 50
Study 8113557 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram mapping approach
Number of subjects: 50
Study 3169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 10/170
Number of subjects: 12
Study 3169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 16/260
Number of subjects: 12
Study 3169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS (both systems)
Number of subjects: 12
Study 3169112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30940217 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant extract supplement (Aloe gel, grape juice, Polygonum cuspidatum)
Number of subjects: 58
Study 30940217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30047573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ 200 mg)
Number of subjects: 76
Study 30047573 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA 81 mg)
Number of subjects: 76
Study 26169646 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction Calibration System (SCS)
Number of subjects: 26
Study 26169646 — intervention group
Group type: COMPARATOR
Intervention: Bougie
Number of subjects: 26
Study 24557326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 100
Study 24557326 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral instrumented fusion (PLF)
Number of subjects: 100
Study 22507333 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0
Study 22507333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 0
Study 22507333 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 0
Study 19464030 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (videoconference with school nurse and diabetes team every month)
Number of subjects: 41
Study 19464030 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medical visits every 3 months, communication as needed)
Number of subjects: 41
Study 19464030 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 41
Study 17239798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (target INR range 2.0-3.0)
Number of subjects: 1068
Study 17239798 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (30-325 mg daily)
Number of subjects: 1068
Study 14872246 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out water immersion (HOI)
Number of subjects: 18
Study 14872246 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out water immersion (HOI) during dynamic exercise
Number of subjects: 18
Study 14872246 — intervention group
Group type: COMPARATOR
Intervention: Control groups (non-diving housewives and non-diving young women)
Number of subjects: 18